Core Viewpoint - Transcat, Inc. (TRNS) is expected to report a quarterly earnings per share (EPS) of $0.66, indicating a 14.3% decline year-over-year, while revenues are projected to increase by 8.3% to $76.8 million [1] Group 1: Earnings and Revenue Estimates - Analysts predict quarterly earnings of $0.66 per share for Transcat, reflecting a 14.3% decline compared to the same period last year [1] - Revenue is forecasted to be $76.8 million, representing an 8.3% year-over-year increase [1] - The consensus EPS estimate has not changed over the past 30 days, indicating stability in analysts' projections [2] Group 2: Key Metrics Forecast - Revenue from Distribution Sales is expected to reach $26.57 million, a year-over-year increase of 9.9% [5] - Service Revenue is projected to be $50.24 million, reflecting a 7.5% increase from the previous year [5] - Gross Profit from Distribution is anticipated to be $8.00 million, up from $7.33 million in the same quarter last year [5] - Gross Profit from Service is expected to reach $16.99 million, slightly above the year-ago figure of $16.70 million [6] Group 3: Market Performance - Transcat shares have shown a return of -5.6% over the past month, contrasting with the Zacks S&P 500 composite's +9.9% change [6] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [6]

Investors might want to bet on Centrus Energy Corp. (LEU) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between ...

Core Viewpoint - Inspired Entertainment (INSE) shows potential as a strong investment opportunity due to significant revisions in earnings estimates, indicating an improving earnings outlook [1][10] Earnings Estimate Revisions - The current quarter's earnings estimate is projected at $0.17 per share, reflecting a substantial increase of +142.86% compared to the previous year [6] - Over the last 30 days, the Zacks Consensus Estimate for the current quarter has risen by 73.68% due to one upward revision and one downward revision [6] - For the full year, the earnings estimate is expected to be $0.95 per share, which is a decrease of -57.78% from the prior year, but the trend remains positive with two upward revisions and no negative revisions, leading to a 71.82% increase in the consensus estimate [7][8] Zacks Rank and Performance - Inspired Entertainment has achieved a Zacks Rank 1 (Strong Buy), which is associated with a strong historical performance, as Zacks 1 Ranked stocks have averaged an annual return of +25% since 2008 [3][9] - The positive estimate revisions have contributed to a 12.9% increase in the stock price over the past four weeks, suggesting further upside potential [10]

Core Viewpoint - BioLife Solutions, Inc. (BLFS) shares have increased by 8.2% recently, with a mean price target of $31.22 suggesting a potential upside of 30.7% from the current price of $23.89 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $1.48, indicating variability among analysts [2] - The lowest price target is $30, representing a 25.6% increase, while the highest target is $34, indicating a potential surge of 42.3% [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about BLFS's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has risen by 19.2% over the past month, with no negative revisions [12] - BLFS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]

Shares of AudioEye (AEYE) have gained 14.3% over the past four weeks to close the last trading session at $12.90, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.40 indicates a potential upside of 73.6%.The mean estimate comprises five short-term price targets with a standard deviation of $2.51. While the lowest estimate of $20 indicates a 55% increase from the current price ...

Shares of Beyond (BYON) have gained 30.8% over the past four weeks to close the last trading session at $5.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.83 indicates a potential upside of 156.1%.The mean estimate comprises six short-term price targets with a standard deviation of $12.16. While the lowest estimate of $5 indicates a 0.2% decline from the current price le ...

Core Viewpoint - Ardent Health Partners, Inc. (ARDT) has shown a significant price increase of 19.4% over the past four weeks, with analysts projecting a mean price target of $20.25, indicating a potential upside of 36.6% from the current price of $14.83 [1] Price Targets and Analyst Consensus - The average price target for ARDT is based on 10 short-term estimates, ranging from a low of $15.50 to a high of $24, with a standard deviation of $2.80, suggesting a variability in analyst predictions [2] - The lowest estimate indicates a 4.5% increase, while the highest suggests a 61.8% upside, highlighting the range of potential outcomes [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ARDT's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.7%, with two estimates moving higher and one lower [12] - ARDT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside in the near term [13]

Clearfield (CLFD) closed the last trading session at $36.36, gaining 37.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $46 indicates a 26.5% upside potential.The average comprises four short-term price targets ranging from a low of $44 to a high of $50, with a standard deviation of $2.71. While the lowest estimate indicates an increase of 21% from the current price level, the m ...

Shares of ClearPoint Neuro, Inc. (CLPT) have gained 18.2% over the past four weeks to close the last trading session at $13.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $27.67 indicates a potential upside of 102.9%.The average comprises three short-term price targets ranging from a low of $25 to a high of $30, with a standard deviation of $2.52. While the lowest estimate ...

Core Viewpoint - Cogent Biosciences, Inc. (COGT) shows significant upside potential with a mean price target of $16.64, indicating a 224.4% increase from the current price of $5.13 [1] Price Targets and Analyst Consensus - The average of 11 short-term price targets ranges from a low of $7 to a high of $24, with a standard deviation of $5.28, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 36.5% increase, while the most optimistic estimate points to a 367.8% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about COGT's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has increased by 3% over the past month, with one estimate going higher and no negative revisions [12] - COGT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]